Cellular Adjuvants for Viral Infection
US-2024299521-A1 · Sep 12, 2024 · US
US9512189B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9512189-B2 |
| Application number | US-201214237133-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 6, 2012 |
| Priority date | Aug 4, 2011 |
| Publication date | Dec 6, 2016 |
| Grant date | Dec 6, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Immunologically active agents are described, including isolated Pneumocystis A 12 protein or polypeptides; immunogenic conjugates containing Pneumocystis A 12 protein or polypeptide of the present invention; antibodies recognizing the Pneumocystis A 12 protein or polypeptide or the immunogenic conjugates of the present invention; and nucleic acid molecules that encode the Pneumocystis A 12 protein or polypeptide of the present invention, as well as DNA constructs, expression vectors, and host cells that contain the nucleic acid molecules. Disclosed uses of the antibodies, immunogenic conjugates, and DNA constructs include inducing passive or active immunity to treat or prevent pathogen infections, particularly by a Pneumocystis organism, in a subject.
Opening claim text (preview).
What is claimed is: 1. An isolated Pneumocystis A12 protein or polypeptide fragment comprising an amino acid sequence that is at least 90% identical to at least a 40 contiguous amino acid sequence of SEQ ID NO:2. 2. A vaccine comprising the isolated protein or polypeptide according to claim 1 . 3. A pharmaceutical composition comprising: the isolated protein or polypeptide according to claim 1 and a pharmaceutically acceptable carrier. 4. A vaccine comprising a fusion protein comprising: a first protein or protein fragment comprising an N-terminal region of Pneumocystis A12 and a second protein or protein fragment linked to the first protein or protein fragment. 5. A pharmaceutical composition comprising: a fusion protein comprising: a first protein or protein fragment comprising an N-terminal region of Pneumocystis A12 and a second protein or protein fragment linked to the first protein or protein fragment and a pharmaceutically acceptable carrier.
Immunostimulants · CPC title
from protozoa · CPC title
Emulsions, e.g. Freund's adjuvant, MF59 · CPC title
Fungal antigens, e.g. Trichophyton, Aspergillus, Candida · CPC title
Antimycotics · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.